3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
48
Carboplatin
34
Pemetrexed
28
Cisplatin
25
Docetaxel
23
Nivolumab
21
Paclitaxel
20
Gemcitabine
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
12
Radiotherapy
12
Cyclophosphamide
12
Radiosurgery
11
130-nm albumin-bound paclitaxel
11
Erlotinib Hydrochloride
10
Bevacizumab
10
osimertinib
9
Cetuximab
8
Temozolomide
7
Taxes
7
Ipilimumab
7
Biopsy
7
fludarabine
6
Ramucirumab
6
Radiation
6
veliparib
5
tislelizumab
5
durvalumab
5
cemiplimab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
bempegaldesleukin
×
Thoracic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts